2026年吉利德科学历年年报/社会责任报告/ESG报告合集（共39套打包）

1、GILEADSCIENCESANNOUNCESTHIRDQUARTER2025FINANCIALRESULTSProductSalesExcludingVekluryIncreased4%Year-Over-Yearto$7.1billionBiktarvySalesIncreased6%Year-Over-Yearto$3.7billionFosterCity,CA,October30,202。

2、1 0 De c e m be r 2 02 4Q325Financial ResultsO ct o be r 30,2 02 5Forward-Looking StatementsStatements included in this document that are not historical in nature are forward-looking statements withi。

3、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549 FORM 10-QQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended Septe。

4、GILEADSCIENCESANNOUNCESSECONDQUARTER2025FINANCIALRESULTSProductSalesExcludingVekluryIncreased4%Year-Over-Yearto$6.9billionBiktarvySalesIncreased9%Year-Over-Yearto$3.5billionFosterCity,CA,August7,2025。

5、1 0 D ec em b er 2 0 2 4Q225Financial ResultsA ug us t 7,2 0 2 5Forward-Looking StatementsStatements included in this press release that are not historical in nature are forward-looking statements wi。

6、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549 FORM 10-QQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended June 。

7、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549 FORM 10-QQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March。

8、GILEADSCIENCESANNOUNCESFIRSTQUARTER2025FINANCIALRESULTSProductSalesExcludingVekluryIncreased4%Year-Over-Yearto$6.3billionBiktarvySalesIncreased7%Year-Over-Yearto$3.1billionFosterCity,CA,April24,2025-。

9、1 0 D ec em b er 2 0 2 4Q125Financial ResultsA p r i l 2 4,2 0 2 5Forward-Looking StatementsStatements included in this press release that are not historical in nature are forward-looking st。

10、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended Dec。

11、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended Dec。

12、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended Dec。

13、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended Dec。

14、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended Dec。

15、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended De。

16、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended De。

17、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended De。

18、GILEAD ANNUAL REPORT 2015Gilead achieved record total revenue of$32.6 billion in 2015,with marked progress across our portfolio of products and pipeline.The company returned about three-quarters of f。

19、Gilead Annual Report 2014We made tremendous progress during the year,introducing new therapies for hepatitis C and cancer while continuing to build on achievements in HIV with regulatory filings for 。

20、ANNUAL REPORT 2013GileadGilead Sciences,Inc.333 Lakeside Drive Foster City,California 94404650 574 3000 T 800 445 3235650 578 9264 FThe approval and introduction of Sovaldi as a treatment for chronic。

21、GILEAD SCIENCES ANNUAL REPORT 2012GILEAD SCIENCES ANNUAL REPORT 2012Gilead Sciences is a biopharmaceutical company that discovers,develops and commercializes innovative therapeutics in areas of unmet。

22、Gilead Sciences Annual Report 2011Our FocusWe are an organization of more than 4,500 individuals working at 31 sites in 24 countries around the world.Together,we share one common focus,and that is ad。

23、GILEAD SCIENCES ANNUAL REPORT 2009MATT PAULSON,PhDResearch Scientist,BiologyGilead Foster City“As captain of Gileads softball team,I know what it takes to win and collaboration is key.The same applie。

24、2007 Annual ReportHaving perspective.Gilead Sciences is a research-based biopharmaceutical company working to expand treatment options and improve the care of people with life-threatening diseases.We。

25、GILEAD SCIENCES 2006 ANNUAL REPORT Gilead Financial HighlightsNotes:The non-GAAP net income for 2004 and 2005 excluded stock-based compensation expense relating to SFAS 123(R)as we began expensing st。

26、STEPPING UP(C C)Stepping UpGILEAD SCIENCES 2005 ANNUAL REPORT Every day,we demonstrate ourREZA OLIYAI,PhD,Formulation and Process DevelopmentSTEPPING UP(1)commitment by stepping up.Stepping up,reachi。

27、 SECURITIES AND EXCHANGE COMMISSION Washington,D.C.20549 FORM 10-K (Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31,。

28、 SECURITIES AND EXCHANGE COMMISSION Washington,D.C.20549 FORM 10-K (Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31,。

29、FORM 10-K GILEAD SCIENCES INC(Annual Report)Filed 3/14/2003 For Period Ending 12/31/2002Address333 LAKESIDE DRFOSTER CITY,California 94404Telephone650-574-3000 CIK0000882095IndustryBiotechnology&。

30、FORM 10-K GILEAD SCIENCES INC(Annual Report)Filed 3/27/2002 For Period Ending 12/31/2001Address333 LAKESIDE DRFOSTER CITY,California 94404Telephone650-574-3000 CIK0000882095IndustryBiotechnology&。

31、FORM 10-K GILEAD SCIENCES INC(Annual Report)Filed 3/20/2001 For Period Ending 12/31/2000Address333 LAKESIDE DRFOSTER CITY,California 94404Telephone650-574-3000 CIK0000882095IndustryBiotechnology&。

32、2023 E N VI R O N M E N TA L S O C I A L G OV E R N A N C E I M PAC T R E P O RTCREATINGREPORTINGINNOVATINGADVANCINGEMPOWERINGSUSTAININGCONTENTS 7/CREATING POSSIBLE 8/About Gilead 10/ESG at Gilead 16。

33、FORM 10-K405 GILEAD SCIENCES INC(Annual Report(Regulation S-K,item 405)Filed 3/30/2000 For Period Ending 12/31/1999Address333 LAKESIDE DRFOSTER CITY,California 94404Telephone650-574-3000 CIK000088209。

34、2024 RESPONSIBLE BUSINESS AND IMPACT REPORT2024 R E S P O N S I B L E B U S I N E S S A N D I M PA C T R E P O R TImpactfor2024 RESPONSIBLE BUSINESS AND IMPACT REPORT2INNOVATE for ImpactABOUT THIS RE。

35、FORM 10-K405 GILEAD SCIENCES INC(Annual Report(Regulation S-K,item 405)Filed 3/22/1999 For Period Ending 12/31/1998Address333 LAKESIDE DRFOSTER CITY,California 94404Telephone650-574-3000 CIK000088209。

36、ENVIRONMENTAL SOCIAL GOVERNANCE IMPACT REPORT2022Greg Klak Vice President,Operations and General Manager,Gilead AlbertaRoderick Mack Financial Assistant,FinanceAna Gonzalez Director,Medicinal Chemist。

37、FORM 10-K405 GILEAD SCIENCES INC(Annual Report(Regulation S-K,item 405)Filed 3/31/1998 For Period Ending 12/31/1997Address333 LAKESIDE DRFOSTER CITY,California 94404Telephone650-574-3000 CIK000088209。

38、任何前瞻性陈述仅以本协议日期或陈述书中指明的日期为准。根据GRIs定义报告内容的原则，吉利德在制定2021年年度回顾时考虑了利益相关者的包容性、可持续性背景、重要性、完整性和其他报告原则。除另有说明外，本报告所载活动和数据涵盖2021年1月1日至2021年12月31日期间。。

39、FORM 10-K405 GILEAD SCIENCES INC(Annual Report(Regulation S-K,item 405)Filed 3/21/1997 For Period Ending 12/31/1996Address333 LAKESIDE DRFOSTER CITY,California 94404Telephone650-574-3000 CIK000088209。